选择性组蛋白去乙酰化酶抑制剂的研究进展
Progress in the Research of Selective Histone deacetylase Inhibitors
摘要: 组蛋白去乙酰化酶(HDACs)参与组蛋白和非组蛋白赖氨酸残基乙酰化和去乙酰化动态平衡过程的调节，它的异常表达与癌症、神经性疾病、炎症、代谢异常等一系列疾病相关。HDAC具有多种亚型，且组织分布及生理功能均有差异，开发亚型选择性HDAC抑制剂可降低其毒副作用，并成为近年来的研究热点，目前已报道多种类型的选择性HDAC抑制剂。本文综述了现阶段选择性HDAC抑制剂的研究进展和潜在适应症。
Abstract: Histone deacetylases (HDACs) play a crucial role in regulating the balance of acetylation and deacetylation of lysine residues of histones and non-histone proteins, whose overexpression is closely associated with a great variety of cancers, neurological diseases, inflammatory diseases, metabolic disorders and so on. HDAC has lots of subtypes, and the tissue distribution and physiological functions are different, the development of subtype selective HDAC inhibitors can reduce its toxic and side effects, and has become a research hotspot in recent years. Several HDAC inhibitors have been reported so far. This review summarizes the current research progress and potential indications of selective HDAC inhibitors.
文章引用：张立园, 万勃亨, 朱雍, 唐伟方. 选择性组蛋白去乙酰化酶抑制剂的研究进展[J]. 材料化学前沿, 2021, 9(1): 9-23. https://doi.org/10.12677/AMC.2021.91002

参考文献

[1] Zhao, C., Dong, H., Xu, Q., et al. (2020) Histone Deacetylase (HDAC) Inhibitors in Cancer: A Patent Review (2017-Present). Expert Opinion on Therapeutic Patents, 30, 263-274.
[Google Scholar] [CrossRef] [PubMed]
[2] Sultana, F., Manasa, K.L., Shaik, S.P., et al. (2019) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry, 26, 7212-7280.
[Google Scholar] [CrossRef] [PubMed]
[3] Zhang, H., Shang, Y.P., Chen, H.Y., et al. (2017) Histone Deacetylase Function as Novel Potential Therapeutic Targets for Cancer. Hepatology Research, 47, 149-159.
[Google Scholar] [CrossRef] [PubMed]
[4] Zhao, C., Zang, J., Ding, Q., et al. (2018) Discovery of Meta-Sulfamoyl N-Hydroxybenzamides as HDAC8 Selective Inhibitors. European Journal of Medicinal Chemistry, 150, 282-291.
[Google Scholar] [CrossRef] [PubMed]
[5] Parra, M. (2015) Class IIa HDACs—New Insights into Their Functions in Physiology and Pathology. The FEBS Journal, 282, 1736-1744.
[Google Scholar] [CrossRef] [PubMed]
[6] Li, T., Zhang, C., Hassan, S., et al. (2018) Histone Deacetylase 6 in Cancer. Journal of Hematology & Oncology, 11, 111.
[Google Scholar] [CrossRef] [PubMed]
[7] Yue, L., Sharma, V., Horvat, N.P., et al. (2020) HDAC11 Deficiency Disrupts Oncogene-Induced Hematopoiesis in Myeloproliferative Neoplasms. Blood, 135, 191-207.
[Google Scholar] [CrossRef] [PubMed]
[8] Thomas, A.M., David, J.W. and Sandro, B. (2003) Histone Deacetylase Inhibitors. Journal of Medicinal Chemistry, 46, 5097-5116.
[Google Scholar] [CrossRef] [PubMed]
[9] Marson, C.M. (2009) Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 9, 661-692.
[Google Scholar] [CrossRef] [PubMed]
[10] Luan, Y., Li, J., Bernatchez, J.A., et al. (2019) Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 62, 3171-3183.
[Google Scholar] [CrossRef] [PubMed]
[11] Hess-Stumpp, H. (2005) Histone Deacetylase Inhibitors and Cancer: From Cell Biology to the Clinic. European Journal of Cell Biology, 84, 109-121.
[Google Scholar] [CrossRef] [PubMed]
[12] Trapani, D., Esposito, A., Criscitiello, C., et al. (2017) Entinostat for the Treatment of Breast Cancer. Expert Opinion on Investigational Drugs, 26, 965-971.
[Google Scholar] [CrossRef] [PubMed]
[13] Fournel, M., Bonfils, C., Hou, Y., et al. (2008) MGCD0103, a Novel Isotype-Selective Histone Deacetylase Inhibitor, Has Broad Spectrum Antitumor Activity in Vitro and in Vivo. Molecular Cancer Therapeutics, 7, 759-768.
[Google Scholar] [CrossRef] 
[14] Graziano, M.J., Spoon, T.A., Cockrell, E.A., et al. (2001) Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI-994 (Acetyldinaline). Journal of Biomedicine and Biotechnology, 1, 52-61.
[Google Scholar] [CrossRef] 
[15] Beckers, T., Burkhardt, C., Wieland, H., et al. (2007) Distinct Pharmacological Properties of Second Generation HDAC Inhibitors with the Benzamide or Hydroxamate Head Group. International Journal of Cancer, 121, 1138-1148.
[Google Scholar] [CrossRef] [PubMed]
[16] Henning, S.W. (2010) 178 Preclinical Characterization of 4SC-202, a Novel Isotype Specific HDAC Inhibitor. European Journal of Cancer—Supplement, 8, 61.
[Google Scholar] [CrossRef] 
[17] Peng, X., Liao, G., Sun, P., et al. (2019) An Overview of HDAC Inhibitors and Their Synthetic Routes. Current Topics in Medicinal Chemistry, 19, 1005-1040.
[Google Scholar] [CrossRef] [PubMed]
[18] Ralph, M. (2015) Inhibitors of Histone Deacetylase. PCT International Application, 2015069693, May 14.
[19] Tang, S., Cheng, B., Zhe, N., et al. (2018) Histone Deacetylase Inhibitor BG45-Mediated HO-1 Expression Induces Apoptosis of Multiple Myeloma Cells by the JAK2/STAT3 Pathway. Anticancer Drugs, 29, 61-74.
[Google Scholar] [CrossRef] 
[20] Malvaez, M., McQuown, S.C., Rogge, G.A., et al. (2013) HDAC3-Selective Inhibitor Enhances Extinction of Cocaine- Seeking Behavior in a Persistent Manner. Proceedings of the National Academy of Sciences of the United States of America, 110, 2647-2652.
[Google Scholar] [CrossRef] [PubMed]
[21] Zhang, M.J., Zhao, Q.C., Xia, M.X., et al. (2020) The HDAC3 Inhibitor RGFP966 Ameliorated Ischemic Brain Damage by Downregulating the AIM2 Inflammasome. The FASEB Journal, 34, 648-662.
[Google Scholar] [CrossRef] 
[22] Wagner, F.F., Lundh, M., Kaya, T., et al. (2016) An Isochemogenic Set of Inhibitors to Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection. ACS Chemical Biology, 11, 363-374.
[Google Scholar] [CrossRef] [PubMed]
[23] Wagner, F.F., Zhang, Y.L., Fass, D.M., et al. (2015) Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chemical Science, 6, 804-815.
[Google Scholar] [CrossRef] 
[24] Hirata, Y., Sasaki, T., Kanki, H., et al. (2018) New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death. Scientific Reports, 8, Article No. 1400.
[Google Scholar] [CrossRef] [PubMed]
[25] Mendoza-Sanchez, R., Cotnoir-White, D., Kulpa, J., et al. (2015) Design, Synthesis and Evaluation of Antiestrogen and Histone Deacetylase Inhibitor Molecular Hybrids. Bioorganic & Medicinal Chemistry, 23, 7597-7606.
[Google Scholar] [CrossRef] [PubMed]
[26] Boissinot, M., Inman, M., Hempshall, A., et al. (2012) Induction of Differentiation and Apoptosis in Leukaemic Cell Lines by the Novel Benzamide Family Histone Deacetylase 2 and 3 Inhibitor MI-192. Leukemia Research, 36, 1304-1310.
[Google Scholar] [CrossRef] [PubMed]
[27] Eyre, T.A., Collins, G.P., Gupta, A., et al. (2019) A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of CXD101 in Patients with Advanced Cancer. Cancer, 125, 99-108.
[Google Scholar] [CrossRef] [PubMed]
[28] Poli, G., Di Fabio, R., Ferrante, L., et al. (2017) Largazole Analogues as Histone Deacetylase Inhibitors and Anticancer Agents: An Overview of Structure-Activity Relationships. ChemMedChem, 12, 1917-1926.
[Google Scholar] [CrossRef] [PubMed]
[29] Ma, N., Luo, Y., Wang, Y., et al. (2016) Selective Histone Deacetylase Inhibitors with Anticancer Activity. Current Topics in Medicinal Chemistry, 16, 415-426.
[Google Scholar] [CrossRef] [PubMed]
[30] Parlet, C.P., Kavanaugh, J.S., Crosby, H.A., et al. (2019) Apicidin Attenuates MRSA Virulence through Quorum-Sensing Inhibition and Enhanced Host Defense. Cell Reports, 27, 187-198.e6.
[Google Scholar] [CrossRef] [PubMed]
[31] Arts, J., King, P., Mariën, A., et al. (2009) JNJ-26481585, a Novel “Second-Generation” Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. Clinical Cancer Research, 15, 6841-6851.
[Google Scholar] [CrossRef] 
[32] Su, G.H., Sohn, T.A., Ryu, B., et al. (2000) A Novel Histone Deacetylase Inhibitor Identified by High-Throughput Transcriptional Screening of a Compound Library. Cancer Research, 60, 3137-3142.
[33] Sharma, V., Koul, N., Joseph, C., et al. (2010) HDAC Inhibitor, Scriptaid, Induces Glioma Cell Apoptosis through JNK Activation and Inhibits Telomerase Activity. Journal of Cellular and Molecular Medicine, 14, 2151-2161.
[Google Scholar] [CrossRef] [PubMed]
[34] Wood, T.E., Dalili, S., Simpson, C.D., et al. (2010) Selective Inhibition of Histone Deacetylases Sensitizes Malignant Cells to Death Receptor Ligands. Molecular Cancer Therapeutics, 9, 246-256.
[Google Scholar] [CrossRef] 
[35] McCourt, C., Maxwell, P., Mazzucchelli, R., et al. (2012) Elevation of c-FLIP in Castrate-Resistant Prostate Cancer Antagonizes Therapeutic Response to Androgen Receptor-Targeted Therapy. Clinical Cancer Research, 18, 3822-3833.
[Google Scholar] [CrossRef] 
[36] Balasubramanian, S., Ramos, J., Luo, W., et al. (2008) A Novel Histone Deacetylase 8 (HDAC8)-Specific Inhibitor PCI-34051 Induces Apoptosis in T-Cell Lymphomas. Leukemia, 22, 1026-1034.
[Google Scholar] [CrossRef] [PubMed]
[37] Suzuki, T., Muto, N., Bando, M., et al. (2014) Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8-Selective Inhibitors. ChemMedChem, 9, 657-664.
[Google Scholar] [CrossRef] [PubMed]
[38] Tng, J., Lim, J., Wu, K.C., et al. (2020) Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation. Journal of Medicinal Chemistry, 63, 5956-5971.
[Google Scholar] [CrossRef] [PubMed]
[39] Hassan, M.M., Israelian, J., Nawar, N., et al. (2020) Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting. Journal of Medicinal Chemistry, 63, 8634-8648.
[Google Scholar] [CrossRef] [PubMed]
[40] Yang, Y.C., Chen, C.N., Wu, C.I., et al. (2013) NBM-T-L-BMX-OS01, Semisynthesized from Osthole, Is a Novel Inhibitor of Histone Deacetylase and Enhances Learning and Memory in Rats. Evidence-Based Complementary and Alternative Medicine, 2013, Article ID: 514908.
[Google Scholar] [CrossRef] [PubMed]
[41] Moffat, D., Patel, S., Day, F., et al. (2010) Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex- 3-yl)-N-hydroxypyrim Idine-5-carboxamide (CHR-3996), a Class I Selective Orally Active Histone Deacetylase Inhibitor. Journal of Medicinal Chemistry, 53, 8663-8678.
[Google Scholar] [CrossRef] [PubMed]
[42] Marek, L., Hamacher, A., Hansen, F.K., et al. (2013) Histone Deacetylase (HDAC) Inhibitors with a Novel Connecting Unit Linker Region Reveal a Selectivity Profile for HDAC4 and HDAC5 with Improved Activity against Chemoresistant Cancer Cells. Journal of Medicinal Chemistry, 56, 427-436.
[Google Scholar] [CrossRef] [PubMed]
[43] Di Giorgio, E., Gagliostro, E. and Brancolini, C. (2015) Selective Class IIa HDAC Inhibitors: Myth or Reality. Cellular and Molecular Life Sciences, 72, 73-86.
[Google Scholar] [CrossRef] [PubMed]
[44] Olsson, A., Björk, A., Vallon-Christersson, J., et al. (2010) Tasquinimod (ABR-215050), a Quinoline-3-Carboxamide Anti-Angiogenic Agent, Modulates the Expression of Thrombospondin-1 in Human Prostate Tumors. Molecular Cancer, 9, 107.
[Google Scholar] [CrossRef] [PubMed]
[45] Mai, A., Massa, S., Pezzi, R., et al. (2005) Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides. Journal of Medicinal Chemistry, 48, 3344-3353.
[Google Scholar] [CrossRef] [PubMed]
[46] Butler, K.V., Kalin, J., Brochier, C., et al. (2010) Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A. Journal of the American Chemical Society, 132, 10842-10846.
[Google Scholar] [CrossRef] [PubMed]
[47] Haggarty, S.J., Koeller, K.M., Wong, J.C., et al. (2003) Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation. Proceedings of the National Academy of Sciences of the United States of America, 100, 4389-4394.
[Google Scholar] [CrossRef] [PubMed]
[48] Tan, J., Cang, S., Ma, Y., et al. (2010) Novel Histone Deacetylase Inhibitors in Clinical Trials as Anti-Cancer Agents. Journal of Hematology & Oncology, 3, 5.
[Google Scholar] [CrossRef] [PubMed]
[49] Jochems, J., Boulden, J., Lee, B.G., et al. (2014) Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology, 39, 389-400.
[Google Scholar] [CrossRef] [PubMed]
[50] Kozikowski, A.P., Tapadar, S., Luchini, D.N., et al. (2008) Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6. Journal of Medicinal Chemistry, 51, 4370-4373.
[Google Scholar] [CrossRef] [PubMed]
[51] Lee, J.H., Mahendran, A., Yao, Y., et al. (2013) Development of a Histone Deacetylase 6 Inhibitor and Its Biological Effects. Proceedings of the National Academy of Sciences of the United States of America, 110, 15704-15709.
[Google Scholar] [CrossRef] [PubMed]
[52] Bergman, J.A., Woan, K., Perez-Villarroel, P., et al. (2012) Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth. Journal of Medicinal Chemistry, 55, 9891-9899.
[Google Scholar] [CrossRef] [PubMed]
[53] Hideshima, T., Qi, J., Paranal, R.M., et al. (2016) Discovery of Selective Small-Molecule HDAC6 Inhibitor for Overcoming Proteasome Inhibitor Resistance in Multiple Myeloma. Proceedings of the National Academy of Sciences of the United States of America, 113, 13162-13167.
[Google Scholar] [CrossRef] [PubMed]
[54] Inks, E.S., Josey, B.J., Jesinkey, S.R., et al. (2012) A Novel Class of Small Molecule Inhibitors of HDAC6. ACS Chemical Biology, 7, 331-339.
[Google Scholar] [CrossRef] [PubMed]
[55] Wagner, F.F., Olson, D.E., Gale, J.P., et al. (2013) Potent and Selective Inhibition of Histone Deacetylase 6 (HDAC6) Does Not Require a Surface-Binding Motif. Journal of Medicinal Chemistry, 56, 1772-1776.
[Google Scholar] [CrossRef] [PubMed]
[56] Kozikowski, A.P., Shen, S., Pardo, M., et al. (2019) Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome. ACS Chemical Neuroscience, 10, 1679-1695.
[Google Scholar] [CrossRef] [PubMed]
[57] Shen, S., Hadley, M., Ustinova, K., et al. (2019) Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. Journal of Medicinal Chemistry, 62, 8557-8577.
[Google Scholar] [CrossRef] [PubMed]
[58] Vergani, B., Sandrone, G., Marchini, M., et al. (2019) Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 62, 10711-10739.
[Google Scholar] [CrossRef] [PubMed]
[59] Martin, M.W., Lee, J.Y., Lancia, D.R., et al. (2018) Discovery of Novel N-Hydroxy-2-Arylisoindoline-4-Carbox- amides as Potent and Selective Inhibitors of HDAC11. Bioorganic & Medicinal Chemistry Letters, 28, 2143-2147.
[Google Scholar] [CrossRef] [PubMed]
[60] Son, S.I., Cao, J., Zhu, C.L., et al. (2019) Activity-Guided Design of HDAC11-Specific Inhibitors. ACS Chemical Biology, 14, 1393-1397.
[Google Scholar] [CrossRef] [PubMed]